MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.17−0.03 (-1.36%)
Close on Nov 16, 2026Market cap $138.23MP/E –Yield –
MacroGenics total assets
Total assets on the balance sheet at the end of each period.
MacroGenics's total assets was $345.41M at Jun 30, 2026. For fiscal 2025 it was $256.85M, down 1.8% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $378.74M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.85M | -1.8% |
| FY2024 | Dec 31, 2024 | $261.66M | -12.3% |
| FY2023 | Dec 31, 2023 | $298.42M | +6.4% |
| FY2022 | Dec 31, 2022 | $280.47M | -16.3% |
| FY2021 | Dec 31, 2021 | $335.25M | -11.5% |
| FY2020 | Dec 31, 2020 | $378.74M | +21.2% |
| FY2019 | Dec 31, 2019 | $312.50M | -5.9% |
| FY2018 | Dec 31, 2018 | $332.13M | -11.2% |
| FY2017 | Dec 31, 2017 | $373.88M | +20.1% |
| FY2016 | Dec 31, 2016 | $311.26M | -13.4% |
| FY2015 | Dec 31, 2015 | $359.27M | +106.6% |
| FY2014 | Dec 31, 2014 | $173.89M | +38.2% |
| FY2013 | Dec 31, 2013 | $125.78M | +134.0% |
| FY2012 | Dec 31, 2012 | $53.75M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $345.41M | +40.7% |
| Q1 FY2026 | Mar 31, 2026 | $217.87M | -3.0% |
| Q4 FY2025 | Dec 31, 2025 | $256.85M | -1.8% |
| Q3 FY2025 | Sep 30, 2025 | $270.76M | +2.4% |
| Q2 FY2025 | Jun 30, 2025 | $245.42M | +22.0% |
| Q1 FY2025 | Mar 31, 2025 | $224.57M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $261.66M | -12.3% |
| Q3 FY2024 | Sep 30, 2024 | $264.49M | -22.2% |
| Q2 FY2024 | Jun 30, 2024 | $201.14M | -34.2% |
| Q1 FY2024 | Mar 31, 2024 | $248.29M | -27.7% |
| Q4 FY2023 | Dec 31, 2023 | $298.42M | +6.4% |
| Q3 FY2023 | Sep 30, 2023 | $339.97M | +74.0% |
| Q2 FY2023 | Jun 30, 2023 | $305.65M | +40.2% |
| Q1 FY2023 | Mar 31, 2023 | $343.50M | +26.5% |
| Q4 FY2022 | Dec 31, 2022 | $280.47M | -16.3% |
| Q3 FY2022 | Sep 30, 2022 | $195.35M | -50.2% |
| Q2 FY2022 | Jun 30, 2022 | $218.04M | -48.8% |
| Q1 FY2022 | Mar 31, 2022 | $271.45M | -37.7% |
| Q4 FY2021 | Dec 31, 2021 | $335.25M | -11.5% |
| Q3 FY2021 | Sep 30, 2021 | $392.16M | +4.7% |
| Q2 FY2021 | Jun 30, 2021 | $425.91M | +30.0% |
| Q1 FY2021 | Mar 31, 2021 | $435.45M | +64.1% |
| Q4 FY2020 | Dec 31, 2020 | $378.74M | +21.2% |
| Q3 FY2020 | Sep 30, 2020 | $374.38M | +6.5% |
| Q2 FY2020 | Jun 30, 2020 | $327.59M | -14.6% |
| Q1 FY2020 | Mar 31, 2020 | $265.41M | -36.0% |
| Q4 FY2019 | Dec 31, 2019 | $312.50M | -5.9% |
| Q3 FY2019 | Sep 30, 2019 | $351.45M | -1.1% |
| Q2 FY2019 | Jun 30, 2019 | $383.68M | -0.8% |
| Q1 FY2019 | Mar 31, 2019 | $414.64M | +27.2% |
| Q4 FY2018 | Dec 31, 2018 | $332.13M | -11.2% |
| Q3 FY2018 | Sep 30, 2018 | $355.36M | +46.9% |
| Q2 FY2018 | Jun 30, 2018 | $386.89M | +40.8% |
| Q1 FY2018 | Mar 31, 2018 | $326.08M | +18.7% |
| Q4 FY2017 | Dec 31, 2017 | $373.88M | +20.1% |
| Q3 FY2017 | Sep 30, 2017 | $241.85M | -28.8% |
| Q2 FY2017 | Jun 30, 2017 | $274.85M | – |
| Q1 FY2017 | Mar 31, 2017 | $274.72M | – |
| Q4 FY2016 | Dec 31, 2016 | $311.26M | – |
| Q3 FY2016 | Sep 30, 2016 | $339.86M | – |
See a number that looks wrong?